Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity

Fig. 2

The effect of ATO on lncRNA Kcnq1ot1, miR-34a-5p, and Sirt1 expression in mouse cardiomyocytes and myocardial tissues. A Predicted binding sites between miR-34a-5p and lncRNA Kcnq1ot1/Sirt1. B The direct binding site between miR-34a-5p and lncRNA Kcnq1ot1 was validated with dual-luciferase reporter assay. C ATO decreased lncRNA Kcnq1ot1 expression in mouse cardiomyocytes. D ATO increased miR-34a-5p expression in mouse cardiomyocytes. E ATO decreased Sirt1 mRNA expression in mouse cardiomyocytes. F ATO decreased Sirt1 protein expression in mouse cardiomyocytes. G ATO decreased lncRNA Kcnq1ot1 expression in mouse myocardial tissues. H ATO increased miR-34a-5p expression in mouse myocardial tissues. I ATO decreased Sirt1 mRNA expression in mouse myocardial tissues. J ATO decreased Sirt1 protein expression in mouse myocardial tissues. For B, one-way ANOVA F value = 362.2. ***P < 0.001. For C–J, *P < 0.05, **P < 0.01, ***P < 0.001 vs. control group; n = 3–6

Back to article page